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Abstract The usefulness of sympathetic skin responses
(SSR) in multiple sclerosis (MS) has been advocated by sev-
eral studies in the last 20 years; however, due to a great het-
erogeneity of findings, a comprehensive meta-analysis of
case-control studies is in order to pinpoint consistencies and
investigate the causes of discrepancies. We searched
MEDLINE, EMBASE and Cochrane databases for case-
control studies comparing SSR absence frequency and latency
between patients with MS and healthy controls. Thirteen eli-
gible studies including 415 MS patients and 331 healthy con-
trols were identified. The pooled analysis showed that SSR
can be always obtained in healthy controls while 34% of pa-
tients had absent SSRs in at least one limb (95% CI 22–47%;
p < 0.0001) but with considerable heterogeneity across studies
(I2 = 90.3%). Patients’ age explained 22% of the overall var-
iability and positive correlations were found with Expanded
Disability Status Scale and disease duration. The pooled mean
difference of SSR latency showed a significant increase in
patients on both upper (193 ms; 95% CI 120–270 ms) and
lower (350 ms; 95% CI 190–510 ms) extremities. We tested
the discriminatory value of SSR latency thresholds defined as
the 95% confidence interval (CI) upper bound of the healthy
controls, and validated the results on a new dataset. The lower
limb threshold of 1.964 s produces the best results in terms of
sensitivity 0.86, specificity 0.67, positive predicted value 0.75
and negative predicted value 0.80. Despite a considerable het-
erogeneity of findings, there is evidence that SSR is a useful
tool in MS.
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Introduction
The sympathetic skin response (SSR) is a simple, reproducible
and non-invasive test based on the modification of the skin
potential elicited most frequently by electrical stimulation of
peripheral nerves. It is one of the methods to assess the auto-
nomic nervous system (ANS) as it involves peripheral pre-
and post-ganglionic sympathetic sudomotor fibres as well as
central structures such as the posterior hypothalamus, upper
brain-stem reticular formation and spinal cord [1].
Multiple sclerosis (MS) is an inflammatory demyelinating
disease with a scattered involvement of the central nervous
system that can also affect the ANS [2]. The ANS can be
impaired in up to 90% of the subjects with multiple sclerosis
(MS) [3]; even if the involvement of the ANS impacts the
quality of life of MS patients [4], it is often overlooked due
to insufficient clinical follow-up and assessment procedures
[3]. The analysis of SSR in MS case-control studies started
around 1990 and spanned a 20 years’ period during which
several small studies have been published advocating the use
of SSR in SM, in spite of a substantial heterogeneity in their
methods and results.
Here, we set out to perform a comprehensive meta-analysis
of case-control studies that have investigated the association
of SSRwithMS.We also ran a simulation study exploiting the
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information of previous studies to evaluate whether a suitable
threshold of SSR latency may discriminate MS patients from
healthy controls, and validated the results on a new dataset
collected by our laboratory. Finally, we attempted to under-
stand the variability of results across studies testing covariates
which may represent meaningful sources of heterogeneity.
Methods
Eligible articles reporting the prevalence of missing SSR
among patients with MS and healthy controls were identified
by searching MEDLINE, EMBASE and the Cochrane
Database of Systematic Reviews databases. Studies published
up to December 2015 were searched using the following com-
bination of search strings: (‘sympathetic skin response OR
SSR’) AND ‘multiple sclerosis’. No language restrictions
were imposed. Reference lists of all articles that met the eligi-
bility criteria were examined to identify studies that may have
been missed by the database search.
Studies were eligible if they met the following criteria: (i)
report of original data in a peer-reviewed publication, (ii) eval-
uation of patients with MS in a case-control setting against a
healthy control group, (iii) use of electrical stimulation of the
limbs to evoke the SSR and (iii) report of the number of
patients and controls with/without the SSR response in at least
one limb and, if available, the SSR latency in the two groups.
Subjects with other neurological disorders in control groups
were excluded from the analysis. Duplicate publications were
also excluded. In the event that the full-text version of a study
did not report clearly the number of patients and controls with
missing SSR response as well as the SSR latency mean (SD)
for both groups, the corresponding author was asked to pro-
vide the missing data in order to maximise the amount of
summarized data. We removed studies whose authors did
not respond. The following data were collected (when avail-
able): journal name, year of publication, number of missing
SSR responses in MS patients and controls, age, sex, type of
MS, disease duration, Expanded Disability Status Scale
(EDSS), SSR stimulation site, SSR intensity and duration,
inter-stimulus interval, skin temperature and SSR latency.
Because none of the controls had missing SSR responses,
we used pooled proportions to evaluate the overall prevalence
of missing responses within theMS patient group. The latency
mean difference between patients and healthy controls was
computed from studies reporting SSR latencies. The fixed-
effects model (Mantel-Haenszel) or random-effects model
(DerSimonian Laird) were used to compute the pooled esti-
mates. Heterogeneity between studies was assessed by the
Cochran Q and I2 statistics. When statistically significant het-
erogeneity was detected (Cochran Q p value < 0.1), random-
effect models were employed. We referred to the I2 statistics
for the qualitative interpretation of heterogeneity; values
greater than 50% are usually considered as indicative of sub-
stantial heterogeneity, while values greater than 75% represent
considerable heterogeneity [5].When a substantial or a greater
amount of heterogeneity was discovered, possible covariates
were tested using mixed-effects meta-regression models when
possible, or explorative correlations in the presence of missing
data [6]. Publication bias was assessed on the overall analysis;
to maximise the power of the test Egger’s statistical test was
performed.
In addition to the meta-analysis study, we tested the 95%
confidence interval of the controls’ pooled mean latency for
both superior and inferior limbs as diagnostic thresholds. We
simulated 5000 data from each study enrolled in the meta-
analysis using their SSR mean and standard deviation (SD)
from both upper and lower limbs and assuming normality;
subsequently, we computed the overall diagnostic odds ratio
(DOR) and the area under the curve (AUC) statistics for su-
perior and inferior limbs for each repetition and extracted
mean and 95% empirical CI.
We recorded the SSR from SM patients and healthy con-
trols to validate our results using the following experimental
setting: we stimulated each limb with a single pulse of 10–20-
mA intensity and 0.2-ms duration and recorded the first elic-
ited ipsilateral response among 3 to 5 stimuli delivered at more
than 60-s interval each. We did not attempt to control limb
temperature through direct warm up of the extremities but
used a wool blanket to maintain the limb temperature during
the entire examination period. All recordings were conducted
using XLTEK® Protector 16-channel averager and statistical
analyses using R version 3.2.3 [7] with packages metafor [6]
and mada [8].
Results
In the first step of the database search, we identified 69 stud-
ies; 16 were from the EMBASE database. After the exclusion
of 23 duplicate studies, the remaining 46 were screened for
eligibility. Out of 28 potentially eligible studies, 15 were ex-
cluded either because of a missing control group (8 studies) or
because of missing information (7 studies) which could not be
recovered but in one case, either because the studies were too
old and the authors could not retrieve their data or because
they did not respond to our request. Data were extracted from
the remaining 13 studies (Table 1 and Fig. 1).
There were three studies from Turkey, two from Iran,
two from Japan and two from the USA. The remaining
studies were conducted in Finland, France, Israel and
Poland. Two studies were published on Journal of
Neurological Sciences and two on Acta Neurologica
Scandinavica. The remaining studies were published on
Annals of Neurology, Brain, Multiple Sclerosis, Clinical
Neurophysiology, Muscle&Nerve, European Neurology,
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Neurologia i Neurochirurgia Polska, Electromyography
and Clinical Neurophysiology.
The total number of MS patients and healthy controls in-
cluded in the final meta-analysis was 415 and 331, respective-
ly. The SSR mean latency and standard deviation (SD) were
not reported in four studies [9–12]. We derived the SD in one
study [13] from the reported range, assuming normality.
Demographic characteristics of patients with MS and healthy
controls are reported in Table 1. SSR recording methods are
reported in Table 2; to avoid habituation, the inter-stimulus
interval was ≥ 30 s in three studies [10, 12, 14], ≥ 45 s in
one study [2], ≥ 60 s in five studies [3, 11, 15–17], ≥ 90 s in
one study [13] and random in two studies [18, 19]. Six studies
kept the skin temperature over 31–32 °C [3, 9–11, 13, 17] and
Table 1 Demographic characteristics ofMS patients and healthy controls enrolled in the case-control studies which were included in the present meta-
analysis. Some data were not available (n/a)
Study Year Country EDSS Duration Total MS Women Control
age Total Age Women
Karaszewski et al. 1990 USA n.a. n.a. 23 n/a n/a 24 n/a n/a
Yokota et al. 1991 Japan n.a. n.a. 28 44 22 50 44.6 n/a.
Gutrecht et al. 1993 USA 3.2 n.a. 29 42(11) 21 26 38(12) 21
Elie et al. 1994 France n.a. n.a. 70 37(11) 45 35 35(8) 24
Drory et al. 1995 Israel 1.8 8.5 60 39 35 30 38 17
Matsunaga et al. 1995 Japan n.a. n.a. 10 n/a n/a 12 32 n/a
Zakrzewska-Pniewska et al. 1996 Poland 4.2(1) 9.8(8) 25 38(7) 13 26 38(11) 13
Alavian-Ghavanini et al. 1999 Iran n.a. 3.8 30 31 20 14 n/a n/a.
Gunal et al. 2001 Turkey 1.8(1) 8(6) 22 37(8) 20 22 38(8) 19
Nazliel et al. 2002 Turkey 2.1(2) 3.7 21 38(11) 13 25 37(10) 13
Secil et al. 2007 Turkey 2.3(0.2) 4.8(0.6) 40 36 40 20 46 20
Saari et al. 2008 Finland 4.2(3) 6.1(5) 27 38(8) 14 27 40(9) 14
Aghamollaii et al. 2011 Iran 1.86 3.1(3) 30 32(9) 15 20 30(8) 11
Present studya 2016 Italy 1.36(1) 10.2(7) 22 36(6) 13 18 34(8) 10
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Fig. 1 Flow chart showing the
selection of eligible studies
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one study over 34 °C [14] while the other six studies did not
report whether they controlled the skin temperature and, if
they did, omitted to report the threshold value.
None of the healthy controls had a missing SSR re-
sponse. The proportion of MS patients with a missing
SSR response varies widely across studies (Fig. 2) rang-
ing from 71% (95% CI 55–88%) in the study of Yokota
et al. (1991) [10] to 8% (95% CI 0–16%) in the more
recent work of Secil et al. (2007) [19].
The pooled analysis showed that the proportion of MS
patients with an absent SSR response is significantly different
from zero (34%; 95% CI 22–47%; p < 0.0001) with consid-
erable heterogeneity across studies (I2 = 90.3%; Q = 123,
p < 0.0001). Patients’ age explained 22% of the total hetero-
geneity indicating that, for instance, a 5-year increase in mean
age adds another 17% to the total proportion of MS patients
with an absent SSR response. Moreover, we found disease
duration to be moderately correlated with the proportion of
MS patients with an absent SSR response (r = 0.35) while
the EDSS was weakly correlated (r = 0.25). No publication
bias was evident (Egger’s test p = 0.68).
The mean difference in the SSR latency between MS pa-
tients and healthy controls varies greatly among studies for
both upper and lower limbs (Figs. 3 and 4). The pooled anal-
ysis in Figs. 3 and 4 showed that the mean difference was
significantly different from zero in the upper limbs (193 ms;
95% CI 120–270 ms) and in the lower limbs as well (350 ms;
95% CI 190–510 ms).
Considerable heterogeneity was apparent in both arms and
legs (I2 = 87.5 and 94%, respectively). The difference in mean
latencies across studies was weakly correlated with EDSS and
disease duration at all limbs; however, all the correlations
increased (EDSS upper limbs: r = 0.77; EDSS lower limbs:
r = 0.81; disease duration upper limbs: r = 0.52; disease du-
ration lower limb: r = 0.53) after removing just one study [3].
The mean SSR latency of the healthy controls’ upper limbs
was 1385 ms (95% CI 1308–1462 ms) and 1915 m (95% CI
1866–1964 ms) in the lower limbs. The results of the simula-
tion study using the upper 95% CI of the healthy controls as a
threshold showed that the diagnostic odds ratio (DOR) for the
upper limbs was 5.81 (95% CI 3.80–8.66) and 6.53 (95% CI
4.1–10.1) for the lower limbs.
The area under the curve was 0.77 (95% CI 0.71–0.83) for
the upper limbs and 0.81 (95% CI 0.74–0.88) for the lower
limbs. The validation on our dataset showed a not significant
DOR for the upper limbs (2.68; 95% CI 0.73–9.8) and a sig-
nificant DOR for the lower limbs (12; 95% CI 2.5–57.5). The
SSR latency threshold of the lower limbs showed a good dis-
crimination ability with a sensitivity of 0.86 (95% CI 0.64–
0.95), a specificity of 0.67 (95% CI 0.44–0.84), a positive
Table 2 SSR recording features for the studies analysed. Some data were not available (n/a). RR relapsing-remitting, SP secondary progressive, PP
primary progressive, CIS clinically isolated syndrome, R right, L left, MT motor threshold





Karaszewski et al. Progressive R foot n/a 0.2 n/a n/a
Yokota et al. Definite MS Supraorb. 10–30 0.2 Shortest of 10 n/a
Gutrecht et al. Definite MS Median 6–12 0.2 Average of 4 n/a
Elie et al. RR, SP, PP R median MT 0.5 n/a n/a
Drory et al. RR, SP R median MT 0.1 First elicited After 4 stimuli of increasing
intensity
Matsunaga et al. n/a R median 20 0.2 Shortest of 8 After a second stimulus of 30 mA
Zakrzewska-Pniewska
et al.
RR, SP R, L median MT 0.5 n/a n/a
Alavian-Ghavanini et al. Definite MS Median 20–60 0.1 Average of 3 to
5
n/a




0.1 n/a After 5 stimuli
Nazliel et al. Definite MS Median and
tibial
6–20 0.2 First elicited After 10 stimuli of increasing
intensity
Secil et al. RR, SP, PP R median 70 0.5 Average of 5 After 10–15 stimuli









> 10 0.2 n/a After 10 stimuli of increasing
intensity
Present studya RR Median and
tibial
10–20 0.2 First elicited After 3 to 5 stimuli
a The data we collected were not used in the meta-analysis but to validate the results of the simulation study
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predicted value (PPV) of 0.75 (95% CI 0.58–0.92) and a neg-
ative predicted value (NPV) of 0.80 (95% CI 0.60–1).
Discussion
To our knowledge, this is the first meta-analysis of case-
control studies to summarize the role of the sympathetic skin
response (SSR) in multiple sclerosis (MS) patients. The
pooled result of our study showed that one-third of MS pa-
tients has no SSR response at least at one limb; on the other
hand, none of the 331 healthy controls in the studies consid-
ered had a missing SSR. These findings suggest that, although
the presence of SSR responses at all limbs cannot rule out the
disease, an absent SSR response should be considered a warn-
ing sign of a pathological condition affecting the central or
peripheral sudomotor subsystem of the ANS [1].
Moreover, an absent or altered SSR in the early phases of
MS may carry additional information that standard clinical
measures, such as the Expanded Disability Status Scale
(EDSS), cannot capture [18]. In addition, SSR testing may
also provide further information when performed alongside
Fig. 2 Forest plot describing the overall proportion of MS patients with at least one SSR absent response
Fig. 3 Forest plot describing the mean difference between MS patients and controls’ SSR upper limb latency
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more popularMS neurophysiological tests, such as the evoked
potentials (EPs). This was suggested by Aghamollai et al. [3],
who reported abnormal or absent SSR also in MS patients
without EP anomalies. We found supporting evidence in our
validation dataset, where one out of 5 patients with an absent
SSR had an EDSS of 1.5 and multimodal sensory evoked
potentials within normal limits.
The pooled analysis of the SSR latency mean difference
showed a significantly longer latency in the MS patients, par-
ticularly in the lower limbs. The latency of the SSRwas longer
for the MS patients compared to that for the controls in all the
studies included in the analysis. This argues against the use-
lessness of SSR latency measurement suggested by some
studies [4, 18]. Furthermore, we showed that the 95% confi-
dence interval (CI) upper limit of SSR latency of the healthy
controls could be a suitable clinical threshold to discriminate
MS patients from healthy subjects. The validation study on
our dataset suggested that the lower limbs threshold (1964ms)
provides better discrimination. The use of a SSR latency
threshold to discriminate MS patients from healthy controls
was also tested by Aghamollai et al. [3] and Alavian-
Ghavanini et al. [14], who reported similar good performances
though they did not further validate their findings.
We found a considerable heterogeneity of both proportion
and mean difference pooled analyses among case-control
studies included in our meta-analysis. Patients’ age explained
nearly 25% of the overall variability of the proportion of pa-
tients with absent SSR across studies. Although it is possible
to consider age as a proxy of disease duration in the MS
framework, it is worth mentioning that in a previous work
[20] the absence of SSR was also related to ageing in healthy
subjects. As a consequence, it is hard to interpret the meaning
of the relationship between mean age and the proportion of
absent SSR we found in the data.
In addition, the exploratory correlations between EDSS
and both the proportion of absent SSR and SSR latency sug-
gested that EDSS may help explain another part of the overall
heterogeneity found in our meta-analysis. This agrees with
some studies [3, 4] where both duration and severity of the
disease were related to the involvement of the ANS.
Other sources of variability may be found in the different
technical setting used to record the SSR. Habituation, body
temperature, stimulus intensity and selection of the evoked
response are important variables to consider [1, 21, 22].
Habituation in healthy subjects causes a progressive de-
crease of SSR amplitude that appears earlier if stimuli are
given at a regular, predictable pace. To minimise habituation,
a random stimulation with a frequency greater than one per
minute is suggested [21]. In the present meta-analysis, we
observed a variety of inter-stimulus intervals ranging from
30 to 90 s, making it possible for shorter intervals to inflate
pathological findings.
Skin temperature was found to be negatively related to
both SSR latency and amplitude in healthy subjects [21,
22], and the local warming of the extremities was shown
to decrease SSR amplitude through depolarization of the
sweat glands [21]. Not all the studies analysed here re-
ported if and how skin temperature was measured and
controlled during SSR recordings; failure to control this
parameter could have also enhanced the heterogeneity of
findings across studies.
It is known that the amplitude of the SSR depends on the
stimulus strength [23] and that a weak stimulus may fail to
induce an arousal response [1]. Due to the wide range of
Fig. 4 Forest plot describing the mean difference between MS patients and controls’ SSR lower limb latency
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intensity and duration of the stimuli reported across studies,
we cannot rule out the possibility that different combinations
of intensity and stimulus duration have influenced the SSR
measures to some extent.
Eventually, it must be stressed that even in studies of
healthy subjects, there is still no consensus on the proper
way to measure the skin responses and their mathematical
processing [21]. The absolute amplitude value of the first
response elicited was suggested to be representative of
the peak amplitude and of the shortest latency; however,
only two studies among those included in the meta-
analysis employed this method. Three studies used av-
eraging, even though it is affected by habituation and
by shape variability across responses [24]. No consensus
is also present on the definition of SSR absence. Some
studies considered SSR absence if no response was elic-
ited after 10 to 15 stimuli; however, in our experience,
3 to 5 stimuli per limb with a minimum inter-stimulus
interval of 1 min increase testing time to an extent
compatible with habituation and subjects’ discomfort.
Together with a considerable heterogeneity, missing data is
another limitation in our study. Several controlling factors could
not be properly tested in our meta-analysis due to missing data,
the main source of which is the lack of a common approach in
the collection of variables across the studies with some failing
to report even standard demographic and clinical information.
Despite these limitations, the pooled results of this meta-
analysis support SSR recording to detect ANS involvement in
MS using the latency or the absence of response as a measure.
Our findings suggest that SSRs yield complementary infor-
mation to that of the EDSS and evoked potentials which could
contribute to the understanding and monitoring of MS.
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